Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8⁺ T and NK cells

Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing anti-tumor immunity

Read more at globenewswire.com